BriaCell Therapeutics (BCT) Stock Price, News & Analysis

Company Overview

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.

Key Stats

• Today's Range: C$4.81 to C$5.09
• 50-Day Range: C$4.13 to C$6.33
• 52-Week Range: C$4.13 to C$49.00
• Volume: 3,864 shs
• Average Volume: 24,401 shs
• Market Capitalization: C$35.31 million
• P/E Ratio: N/A
• Dividend Yield: 13.70%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:BCT
• CIK: N/A
• Web: www.briacell.com
• Phone: 604-921-1810
• Fax: N/A
• Employees: 16
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($14.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$2.37 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -166.26%
• Return on Assets: -122.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.19
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$10.79 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 7,250,000
• Free Float: N/A
• Market Cap: C$35.31 million
• Optionable: Not Optionable
• Beta: 1.95